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Dear Editor
Quality improvement is the mainstay of the modern 
healthcare system, having the goals of improving quality of 
care and ensuring patient safety (1). An interesting and cur-
rent topic in the quality improvement field is thrombophilia 
testing for venous thromboembolic events (VTEs).VTE is 
classified into provoked and unprovoked types. Provoked 
VTE, especially in some younger patients, can lead clini-
cians to test for thrombophilia, to hopefully prevent future 
VTE episodes (2). However, if done inappropriately, this 
testing can put a significant burden on healthcare systems.
At the University of Toledo Medical Center, we con-
ducted a retrospective analysis of patients with document-
ed VTE, to evaluate the appropriateness of thrombophilia 
testing and its effect on management (3,4). We divided pa-
tients into two groups: low risk (first provoked VTE or upper 
extremity VTE) and high risk (first unprovoked VTE, two 
or more episodes of VTE, age < 45 years, positive family 
history of VTE, unusual location, and arterial thrombosis). 
Approximately 41% of patients were assessed as low risk 
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and 59% were assessed as high risk. Based on our interim 
data analysis, we found that thrombophilia testing was done 
on a relatively small subset of low risk (6.8%) and high 
risk (22.7%) patients, which was very encouraging. At our 
center, the cost of testing for hereditary thrombophilia was 
$6,172 per patient. Even in the high-risk group, in more than 
half of patients who were tested for thrombophilia, testing 
did not change the management.
Based on current evidence and on the fact that throm-
bophilia testing rarely changes the management plan (even 
for high-risk patients), I think the testing is being overused. 
High-risk patients have enough high-risk indicators to justify 
continuation of anticoagulation regardless of thrombophilia 
testing results. The cost of thrombophilia testing is extreme-
ly high without, in most circumstances, having a significant 
effect on patient care.
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